Business
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
Icovamenib is an oral covalent menin inhibitor in clinical development to investigate its impact on the function of insulin-producing beta cells REDWOOD CITY,
About this update from Biomea Fusion, Inc.
[{"type":"text","content":"Icovamenib is an oral covalent menin inhibitor in clinical development to investigate its impact on the function of insulin-producing beta cells\nREDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that the World Health Organization (WHO) has approved “icovamenib” as the International Nonproprietary Name (INN) for its lead product candidate BMF-219, and that the United States Adopted Name Council has adopted “icovamenib” as the United States Adopted Name (USAN) for BMF-219. The suffix ‘-menib’ stands for menin inhibitor. An International Nonproprietary Name (INN) is a unique, globally recognized name for a pharmaceutical drug or active ingredient. A United States Adopted Name (USAN) is a nonproprietary name selected by the USAN Council to ensure safety, consistency and logic in the choice of names of US medications; the USAN Council, is co-sponsored by the American Medical Association, the United States Pharmacopeial Convention, and the American Pharmacists Association. WHO’s INN Expert Group and the USAN Council approve simple, informative and unique nonproprietary names, also known as generic names. Biomea will use “icovamenib” in upcoming presentations, publications and public statements as the company advances the clinical development of the product candidate. To learn more about icovamenib and its potential impact in diabetes please visit our website at https://biomeafusion.com/diabetes-obesity. About Biomea FusionBiomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response. We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-bindi...